




LINK-J & FIRM Call for Speakers to the 11th Edition of the Business Partnering Event:

Regenerative Medicine Crossroad in Tokyo #11



Crossroad

A crossroad is where people meet, where discussions start, and where friendships begin. We have organized this event series to facilitate effective networking between those seeking partners or licensees in Japan in order to develop their products or to germinate their technology seeds and relevant local companies.

Target Organizations for Speakers

Typically, targeted organizations are clinical development companies or technology seed holders who seek partners in order to bring their clinical development programs to, or look for licensees in Japan.


Event Structure

This half-day session consists of concurrent oral presentations and multiple one-on-one partnering meetings, followed by a networking mixer.

Demographics

We have successfully accommodated 51 speaker groups and over 800 individuals as attendees over the previous ten editions. The demographics are shown below.


Demographics of RMCR Audience #1-#10



Demographics of RMCR Speakers (Business Field) #1-#10



Demographics of RMCR Speakers (Origin) #1-#10



Outline of the 11th event

Tentative Date: Thursday, February 6, 2020 (JST)

Location/Venue: Conference Room, Nihonbashi Life Science Building 2F, Tokyo, Japan

Projected Number of Entries: 3 to 6 partner-seeking organizations

Terms of Entry: Free entry; No compensation will be offered by FIRM for any costs incurred before, during, or after participation (e.g., transportation or expenses)

Registration Deadline for the Event: Friday, November 29, 2019, (JST)

Contact: Fuyuhiko Mori, RMCR Organizer; info-tf@firm.or.jp

Note: Either FIRM or LINK-J does not guarantee that you will participate in the Event even if you apply for participation as a partner seeker, and it does not guarantee that you will find a business partner during the Event. Please note that the information provided or presented by you in the Event shall not be treated as confidential. Further, you should make sure that you will not provide or present any information that is untrue, incorrect, or misleading. You are solely liable and either FIRM or LINK-J shall NOT be liable for any losses, damages, or expenses of any kind incurred by the audiences or partners due to or in connection with any information or otherwise provided by you during the Event. Either FIRM or LINK-J shall not be liable for any acts or omissions of the audiences or partners. If any disputes or problems are raised between you and the audiences or partners, it is your responsibility to resolve them by yourself.

Regenerative Medicine Crossroad® in Tokyo Track Records

Speakers who took advantages of the Events #1~#10 (In alphabetical order)

Asterias Biotherapeutics (#1)	(Fremont, CA, USA)
AVM Biotechnology (#2)	(Seattle, WA, USA)
BioCardia Inc. (#9)	(San Carlos, CA, USA)
BIOrACT – 3B’s Research Group (#8)	(Guimaraes, Portugal)
Caladrius Biosciences (#1, #9)	(Basking Ridge, NJ, USA)
Cell and Gene Therapy Catapult (#10)	(London, UK)
Cellatoz Therapeutics, Inc. (#10)	(Seongnam, Republic of Korea)
Cellink (#8)	(Gothenburg, Sweden)
Cynata Therapeutics Ltd. (#2)	(Armadale, VIC, Australia)
ECBio S.A. (#1)	(Lisbon, Portugal)
Elk OrthoBiologics Ltd. (#5)	(Hawthorn East, VIC, Australia)
EUTILEX Co., Ltd. (#10)	(Seoul, Republic of Korea)
ExTherea (#8)	(Tokyo, Japan)
Feldan Therapeutics (#3)	(Quebec City, QC, Canada)
GN Corp. Co., Ltd. (#1)	(Kofu, Japan)
Gwo-Xi Stem Cell Applied Technology Co. (#5)	(Zhubei City, Hsinchu, Taiwan)
Histogenics Corp. (#4)	(Waltham, MA, USA)
Hokkaido University, School of Medicine (#1)	(Sapporo, Japan)
ImmunisBio Co., Ltd. (#4)	(Incheon, Republic of Korea)
Innovacell Biotechnologie AG (#10)	(Innsbruck, Austria)
JBM Inc. (#7)	(Tokyo, Japan)
Jiksak Bioengineering Inc. (#6)	(Tokyo, Japan)
Juventas Therapeutics, Inc. (#3)	(Cleveland, OH, USA)
Kangstem Biotech Co., Ltd. (#8)	(Seoul, Republic of Korea)
Kyoto University (#10)	(Kyoto, Japan)
Longeveron LLC (#7)	(Miami, FL, USA)
Maria Von Med-Biotechnology Co., Ltd. (#5)	(New Taipei, Taiwan)
Medipost Co., Ltd. (#6)	(Seongnam, Republic of Korea)
Miltenyi Biotec K.K. (#4)	(Tokyo, Japan)
Miromatrix Medical Inc. (#9)	(Eden Prairie, MN, USA)
NeuroSyntek Modeling & Manufacturing (#4)	(Los Altos, CA, USA)
NexImmune, Inc. (#7)	(Gaithersburg, MD, USA)
Nutech Mediworld (#7)	(New Delhi, India)
Promethera Biosciences S.A. (#5)	(Mont-Saint-Guibert, Belgium)
QIMR Berghofer Medical Research Institute (#9)	(Herston, QLD, Australia)
Regeneus Ltd. (#2)	(Pymble, NSW, Australia)
S Biomedics Co., Ltd. (#8)	(Seoul, Republic of Korea)
SCM Lifescience Co., Ltd. (#6)	(Incheon, Republic of Korea)
Stemedica International, S.A. (#2)	(Lausanne, Switzerland)
Stement Biotherapeutics, Inc. (#7)	(Taipei, Taiwan)
Stempeutics Research Pvt. Ltd. (#2)	(Bangalore, India)
STRI-bBHC (#3)	(Seoul, Republic of Korea)
Takara Bio Inc. (#2)	(Kusatsu, Japan)
Transwell Biotech Co., Ltd. (#6)	(Hsinchu, Taiwan)
The University of Tokushima, Graduate School (#7)	(Tokushima, Japan)
The University of Tokyo, School of Medicine (#3)	(Tokyo, Japan)
Thrive Bioscience, Inc. (#10)	(Wakefield, MA, USA)
Vericel Corp. (#1)	(Cambridge, MA, USA)
Videreg Ltd. (#3)	(Liverpool, Merseyside, UK)



Please find a Preliminary Registration Form on the website →